[1] M. MAUTINO. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.[J]. Cancer research, 2013, 73 1: 491-491. DOI:
10.1158/1538-7445.am2013-491[2] MINGHUI LI. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.[J]. Journal for Immunotherapy of Cancer, 2014, 2: 21. DOI:
10.1186/2051-1426-2-21[3] XIANGJING MENG. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.[J]. International Journal of Immunopathology and Pharmacology, 2017, 30 3: 215-226. DOI:
10.1177/0394632017714696